Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (373)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 51 to 60 of 383
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Technology appraisal guidance
5 March 2025
Cardiometabolic disease prevention and treatment guidelines
NICE guideline
TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Technology appraisal guidance
TBC
Previous page
1
…
4
5
Current page
6
7
8
…
39
Page
6
of
39
Next page
Results per page
10
25
50
All
Back to top